Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As2O3) and all-trans retinoic acid (ATRA)

Jain, Preetesh; Konoplev, Sergej; Benjamini, Ohad; Romagura, Jorge; Burger, Jan A.

doi:10.5045/br.2018.53.2.169

Cited by 2 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[26,27]. In that respect, clinical responses to solid tumors were observed in some RA/ATO-treated APL patients who presented a synchronous another malignancy [47,48], possibly reflecting activation of the RA/Pin1/PML/P53 axis unraveled by this study. Gene set enrichment analysis was performed using Hallmarks (h.all.v7.1) gene set database which contains 50 pathway gene sets.…”

Section: Discussionmentioning

confidence: 54%

“… 13 , 16 More broadly, the RA/ATO combination could target malignancies in which Pin1 and/or PML are deregulated. 26 , 27 In this respect, clinical responses by solid tumors were observed in some RA/ATO-treated APL patients who had another synchronous malignancy, 47 , 48 possibly reflecting activation of the RA/Pin1/PML/P53 axis elucidated by this study.…”

Section: Discussionmentioning

confidence: 56%

See 1 more Smart Citation

A Pin1/PML/P53 axis activated by retinoic acid in NPM-1c acute myeloid leukemia

Hleihel

Hajj²,

et al. 2021

haematol

View full text Add to dashboard Cite

Retinoic acid (RA) was proposed to increase survival of chemotherapy-treated Nucleophosmin-1 mutated Acute Myeloid Leukemia patients (NPM-1c AMLs). We reported that ex vivo, RA triggers NPM-1c degradation, P53 activation and growth arrest. PML organizes domains that control senescence or proteolysis. Here, we demonstrate that PML is required to initiate RA-driven NPM-1c degradation, P53 activation and cell death. Mechanistically, RA enhances PML basal expression through inhibition of activated Pin1, prior to NPM-1c degradation. Such PML induction drives P53 activation, favoring blasts response to chemotherapy or arsenic in vivo. This RA/PML/P53 cascade could mechanistically explain RA-facilitated chemotherapy response in NPM-1c AML patients.

show abstract

Section: Discussionmentioning

confidence: 54%